The six universities will collaborate with industry and clinicians to develop tools for stratifying patients based on their response to certain therapies.
Roche's Cobas EGFR v2 mutation test will be able to identify advanced NSCLC patients with EGFR mutations who are likely to benefit from the next-generation treatment.
Qiagen posted revenues of $319.5 million compared to $330.8 million in the year-ago period, and beat analysts' consensus estimate on the top and bottom lines.
The firm increased its MDx revenues 7 percent from a year ago and beat the consensus Wall Street estimates on the top and bottom lines.
Revenues increased to $22.5 million in Q2, but investors shed shares in the firm after it lowered its revenue guidance for FY 2015.
In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.
The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.
A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.
The US is heading toward another budget showdown, Nature News says.